Stuttgart - Delayed Quote EUR

Karolinska Development AB (2I9.SG)

0.0636

+0.0006

+(0.95%)

At close: April 25 at 8:05:35 AM GMT+2

Notice of Annual General Meeting in Karolinska Development AB (publ)

The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048, (“Karolinska Development” or the “Company”) are invited to the Annual General Meeting, on Thursday May 15, 2025, at 3:00 p.m. (CEST), at Nanna Svartz väg 2, 171 65 Solna, Sweden. The Board of Directors has resolved that shareholders shall have the right to exercise their voting rights in advance through postal voting pursuant to item 13 in the articles of association. Therefore, shareholders may choose to exercise their

GlobeNewswire 19 days ago

KDEV.ST
Karolinska Development’s portfolio company Umecrine Cognition appoints new CEO

STOCKHOLM, SWEDEN – April 1, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) annouces that Viktor Drvota today takes over as CEO of the portfolio company Umecrine Cognition. Viktor Drvota remains the CEO of Karolinska Development. Umecrine Cognition is developing a new class of drugs to alleviate cognitive symptoms caused by liver disease. The company's most advanced drug candidate, golexanolone, is currently being evaluated in a clinical phase 1b/2a study in patients with primary bilia

GlobeNewswire 25 days ago

KDEV.ST
Karolinska Development’s portfolio company Umecrine Cognition presents promising preclinical Parkinson data at AD/PD 2025

STOCKHOLM, SWEDEN – April 1, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition presents recent preclinical data showing that golexanolone reverses dopamine loss and sustains improvements of Parkinsonian symptoms at the 19th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) 2025, in Vienna, Austria, April 1–5th. Parkinson’s disease is a progressive neurodegenerative disease hallmarked by motor symptoms and

GlobeNewswire 25 days ago

KDEV.ST
Karolinska Development Annual Report 2024 published

STOCKHOLM, SWEDEN – March 21, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces publication of its Annual Report 2024. The report is now available to download at www.karolinskadevelopment.com For further information, please contact: Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Hans-Christoffer “HC” Toll, CFO, Karolinska Development AB Phone: +46 70 717 00 41, e-mail: hc.toll@karolinskadevelopment.com

GlobeNewswire last month

KDEV.ST
Karolinska Development’s portfolio company Umecrine Cognition provides update on ongoing Phase 1b/2a clinical study

STOCKHOLM, SWEDEN – March 18, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has provided an update regarding the ongoing clinical phase 1b/2a trial evaluating the drug candidate golexanolone in PBC patients. Due to technical issues in the production of capsules used in the study, the clinical trial has been delayed. No patient safety concerns have been noted, and Umecrine Cognition is working intensively together with its s

GlobeNewswire last month

KDEV.ST
Karolinska Development’s portfolio company AnaCardio has been granted additional EU patent for drug candidate AC01

STOCKHOLM, SWEDEN March 13, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has been granted patent for its drug candidate AC01 as an inotropic agent in the EU. AnaCardio AB is a privately held Swedish clinical-stage biopharmaceutical company developing novel drugs to treat heart failure. The company´s lead asset, AC01, is currently being evaluated in a clinical phase 1b/2a study, GOAL-HF1, in patients with heart failure and reduced e

GlobeNewswire last month

KDEV.ST
Karolinska Development's portfolio company PharmNovo receives positive FDA feedback prior to IND application for Phase 2a trial

STOCKHOLM, SWEDEN – March 12, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that portfolio company PharmNovo received positive feedback regarding its most advanced drug candidate, PN6047, in a pre-IND meeting with the U.S. Food and Drug Administration (FDA). The meeting aimed to provide guidance on the design of the company's planned Phase 2a clinical trial for the treatment of peripheral neuropathy and allodynia. PharmNovo conducted a regulatory pre-IND Type B meeting

GlobeNewswire last month

KDEV.ST
Karolinska Development’s portfolio company AnaCardio includes first patient in a phase 2a study of its drug candidate AC01

STOCKHOLM, SWEDEN February 25, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has dosed the first patient in the phase 2a part of the GOAL-HF1 clinical study. The study will evaluate AnaCardio’s drug candidate AC01 in patients with heart failure and reduced ejection fraction. Study results from GOAL-HF1 are expected by the end of the year. AnaCardio AB is a privately held Swedish clinical-stage biopharmaceutical company developing no

GlobeNewswire last month

KDEV.ST
Karolinska Developments portfolio company Promimic publishes positive results on reduction of bacteria growth on HAnano Surface

STOCKHOLM, SWEDEN, February 18 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Promimic has published positive results showing a reduction of bacterial growth on the company’s implant surface HAnano Surface. The results are published in the Journal of Functional Biomaterials. Promimic has previously seen an effect on reduced adhesion of bacteria on HAnano Surface, but the recent results also show a reduction of bacterial growth. The results ind

GlobeNewswire 2 months ago

KDEV.ST
Year-end Report - January-December 2024

STOCKHOLM – 14 February 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Year-end Report January-December 2024. The full report is available on the Company's website. “Stronger liquidity will ensure our ongoing ability to continue advancing the portfolio companies who are at earlier stages in the development phase and offer the potential for creating substantial value going forward”, says Viktor Drvota, CEO, Karolinska Development. Significant events during the fourth

GlobeNewswire 2 months ago

KDEV.ST
Karolinska Development’s portfolio company Dilafor advances tafoxiparin following successful meetings with FDA and European regulatory authorities

STOCKHOLM, SWEDEN – January 30, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilafor has successfully completed regulatory meetings with the U.S. Food and Drug Administration, FDA, and European Health Agencies, regarding the continued development of the company’s drug candidate tafoxiparin. The completed meetings mark the end of a comprehensive dialogue with regulatory authorities in the US and EU to reach an alignment between the authoritie

GlobeNewswire 2 months ago

KDEV.ST
Karolinska Development’s portfolio company AnaCardio raises SEK 205 million and reports positive Phase 1b data of AC01

STOCKHOLM, SWEDEN January 9, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has secured SEK 205 million in a series A extension financing round and reports positive results from the first part of a Phase 1b/2a study of AC01 in patients with heart failure and reduced ejection fraction. The final part of the study (phase 2a) is expected to start during the first quarter of 2025. AnaCardio AB is a Swedish privately held, clinical-stage

GlobeNewswire 3 months ago

KDEV.ST
Karolinska Development’s portfolio company Umecrine Cognition raises MSEK 23.8 to continue clinical development of golexanolone

STOCKHOLM, SWEDEN – December 19, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the portfolio company Umecrine Cognition has raised SEK 23.8 million through a convertible loan to be used for the continuation of the company’s clinical study of golexanolone in primary biliary cholangitis. The convertible loan with attached share options is directed to a consortium of investors. Umecrine Cognition is currently enrolling patients in the second part of the company’s cli

GlobeNewswire 4 months ago

KDEV.ST
Karolinska Development’s Board of Directors appoints Ben Toogood as new Chairman

STOCKHOLM, SWEDEN – December 18, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the company’s Board of Directors has appointed Ben Toogood as new Chairman until the next General Meeting. Karolinska Development’s Board of Directors has internally appointed its member Ben Toogood as new Chairman, following Professor Hans Wigzell’s resignation from the position at his own request. Ben Toogood has been a member of the Board since 2021 and is beyond the assignment also

GlobeNewswire 4 months ago

KDEV.ST
Karolinska Development’s Chairman of the Board resigns at his own request

STOCKHOLM, SWEDEN – December 11, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the company’s Chairman of the Board, Professor Hans Wigzell, has decided to resign from his position. The Board of Directors will immediately initiate a process to appoint a new Chairman. Hans Wigzell has been an instrumental force in Karolinska Development ever since the company was founded. He has served as Chairman of the Board during several periods, most recently since the 2024 Ann

GlobeNewswire 4 months ago

KDEV.ST
Karolinska Development divests 4,6 million shares in portfolio company OssDsign

STOCKHOLM, SWEDEN, December 10, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) divests 4,6 million shares in the portfolio company OssDsign and thereby strengthens the investment company’s liquidity. Karolinska Development holds nearly 5 million shares in OssDisgn after the divestment. The divestment is being carried out in two stages, as the acquirer, Linc AB, following the transaction, will exceed (directly and indirectly) 10 percent of the voting rights in OssDsign. On December 10,

GlobeNewswire 4 months ago

KDEV.ST
Karolinska Development's portfolio company Modus Therapeutics initiates a phase 2 study with sevuparin for treatment of chronic kidney disease with anemia

STOCKHOLM, SWEDEN – December 9, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has dosed the first patient in a phase 2 clinical study of the drug candidate sevuparin, evaluated as a treatment for chronic kidney disease with anemia. The study is being conducted at Centro Ricerche Cliniche di Verona in Italy. Modus Therapeutics, listed on Nasdaq First North Growth Market, has initiated a clinical phase 2 study where the dru

GlobeNewswire 4 months ago

KDEV.ST
Karolinska Development implements organizational changes for more efficient portfolio management

STOCKHOLM, SWEDEN – December 2, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the company has decided to implement organizational changes in order to reduce the cost base of its operations. The changes involve reducing the management team by one person and giving notice of redundancy to a total of three employees. This is estimated to reduce the company's personnel costs by approximately 20 percent. Within the framework of a strategic review, Karolinska Developmen

GlobeNewswire 4 months ago

KDEV.ST
Karolinska Development's portfolio company Modus Therapeutics secures bridge financing

STOCKHOLM, SWEDEN November 19, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has secured access to bridge financing of up to SEK 5 million from Karolinska Development, the company’s largest shareholder. The funding enables Modus to initiate the recently approved phase 2a study in chronic kidney disease. ”Modus Therapeutics research is gaining momentum and with this funding they now have the opportunity to maintain a good pa

GlobeNewswire 5 months ago

KDEV.ST
Karolinska Development’s portfolio company Umecrine Cognition presents positive interim data from Phase 1b/2a clinical study

STOCKHOLM, SWEDEN – November 18, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition will present data from a recent interim analysis from an ongoing Phase 1b/2a clinical study of golexanolone in patients with Primary Biliary Cholangitis. The preliminary results show that golexanolone was well-tolerated and achieved drug exposure levels that correlate to clinical treatment doses. The results will be presented at the Late Breaking

GlobeNewswire 5 months ago

KDEV.ST

Performance Overview

Return	2I9.SG	OMX Stockholm 30 Index (^OMX)
YTD	-10.17%	-2.26%
1-Year	-46.19%	-3.90%
3-Year	-60.25%	+18.35%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Karolinska Development AB (2I9.SG)

Notice of Annual General Meeting in Karolinska Development AB (publ)

Karolinska Development’s portfolio company Umecrine Cognition appoints new CEO

Karolinska Development’s portfolio company Umecrine Cognition presents promising preclinical Parkinson data at AD/PD 2025

Karolinska Development Annual Report 2024 published

Karolinska Development’s portfolio company Umecrine Cognition provides update on ongoing Phase 1b/2a clinical study

Karolinska Development’s portfolio company AnaCardio has been granted additional EU patent for drug candidate AC01

Karolinska Development's portfolio company PharmNovo receives positive FDA feedback prior to IND application for Phase 2a trial

Karolinska Development’s portfolio company AnaCardio includes first patient in a phase 2a study of its drug candidate AC01

Karolinska Developments portfolio company Promimic publishes positive results on reduction of bacteria growth on HAnano Surface

Year-end Report - January-December 2024

Karolinska Development’s portfolio company Dilafor advances tafoxiparin following successful meetings with FDA and European regulatory authorities

Karolinska Development’s portfolio company AnaCardio raises SEK 205 million and reports positive Phase 1b data of AC01

Karolinska Development’s portfolio company Umecrine Cognition raises MSEK 23.8 to continue clinical development of golexanolone

Karolinska Development’s Board of Directors appoints Ben Toogood as new Chairman

Karolinska Development’s Chairman of the Board resigns at his own request

Karolinska Development divests 4,6 million shares in portfolio company OssDsign

Karolinska Development's portfolio company Modus Therapeutics initiates a phase 2 study with sevuparin for treatment of chronic kidney disease with anemia

Karolinska Development implements organizational changes for more efficient portfolio management

Karolinska Development's portfolio company Modus Therapeutics secures bridge financing

Karolinska Development’s portfolio company Umecrine Cognition presents positive interim data from Phase 1b/2a clinical study

Performance Overview